课题基金 / 基金详情

miRNA Regulation of Macrophages after Spinal Cord Injury

miRNA Regulation of Macrophages after Spinal Cord Injury
脊髓损伤后巨噬细胞的 miRNA 调控
批准号:
8539110
负责人:
Mireia Guerau-de-Arellano
金额:
$18.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-01 至 2015-08-31

项目摘要

项目成果

Mireia Guerau-de-Arellano的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):脊髓损伤(SCI)后,“M1”(促炎)和“M2”(抗炎)巨噬细胞聚集在病变部位。M1巨噬细胞,引起神经毒性和阻碍神经再生,持续在SCI病变。相反,支持轴突生长且无神经毒性的M2巨噬细胞在几天后消失。M2巨噬细胞的这种进行性“损失”被认为是由于新活化的小胶质细胞和浸润的单核细胞在急性SCI环境中响应促炎性线索时转化为M1细胞。到目前为止,这种现象阻碍了利用M2巨噬细胞的再生能力来改善SCI恢复的尝试。因此,积极寻求在高度炎症性SCI环境中抑制M1和增强M2巨噬细胞的治疗策略。我们最近发现了M1分化所需的特定microRNA(miRNA)。miRNA是转录后调节基因表达网络的小RNA,有助于细胞分化和谱系选择。我们预测,这种miRNA的特异性调节将降低SCI后M1/M2巨噬细胞的比例,从而提高SCI后组织修复的效率和程度。这一假设将在SCI的体内模型中进行测试,使用缺乏这种特定mRNA的小鼠,并开发出一种用特定miRNA抑制剂调节巨噬细胞表型的药理学策略。由于可以操纵miRNA来治疗人类疾病,这些研究将为开发有前途的新疗法提供基础。此外,了解这种特定的miRNA如何通过调节M1/M2平衡来控制炎症,将对调节其他疾病(如动脉粥样硬化,伤口愈合和癌症)中巨噬细胞介导的炎症(或免疫抑制)具有重要意义。
英文摘要
DESCRIPTION (provided by applicant): After spinal cord injury (SCI), "M1" (pro-inflammatory) and "M2" (anti-inflammatory) macrophages populate the lesion site. M1 macrophages, which cause neurotoxicity and hamper neuroregeneration, persist in SCI lesions. In contrast, M2 macrophages, which support axon growth and are not neurotoxic, disappear after a few days. This progressive "loss" of M2 macrophages is thought to be due to the conversion of newly activated microglia and infiltrating monocytes into M1 cells as they respond to pro- inflammatory cues in the acute SCI environment. This phenomenon has so far impeded attempts to harness the regenerative power of M2 macrophages to improve SCI recovery. Therefore, therapeutic strategies that suppress M1 and enhance M2 macrophages in the highly inflammatory SCI environment are actively sought. We have recently identified a specific microRNA (miRNA) required for M1 differentiation. miRNA are small RNAs that post-transcriptionally regulate gene expression networks, contributing to cell differentiation and lineage choice. We predict that specific modulation of this miRNA will reduce the ratio of M1/M2 macrophages after SCI, thereby improving the efficiency and extent of tissue repair after SCI. This hypothesis will be tested in an in vivo model of SCI, using mice deficient for this specific mRNA, and developing a pharmacologic strategy to modulate macrophage phenotype with specific miRNA inhibitors. Since miRNA can be manipulated to treat human disease, these studies will provide the basis for development of promising new therapies. In addition, understanding how this specific miRNA controls inflammation through regulation of the M1/M2 balance will have important implications to regulation of macrophage-mediated inflammation (or immune suppression) in other conditions, such as atherosclerosis, wound healing and cancer.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3389/fimmu.2017.01520
发表时间: 2017
期刊: Frontiers in immunology
影响因子: 7.3
作者: [Amici SA, Dong J, Guerau-de-Arellano M]
通讯作者: Guerau-de-Arellano M
Control of the Inflammatory Macrophage Transcriptional Signature by miR-155.
miR-155 对炎症巨噬细胞转录特征的控制。
DOI: 10.1371/journal.pone.0159724
发表时间: 2016
期刊: PloS one
影响因子: 3.7
作者: [Jablonski KA, Gaudet AD, Amici SA, Popovich PG, Guerau-de-Arellano M]
通讯作者: Guerau-de-Arellano M
Novel knockout models to analyze CD38 function
  • 批准号:
    10177865
  • 项目类别:
  • 资助金额:
    $7.8万
  • 财政年份:
    2020
  • 负责人:
    Mireia Guerau-de-Arellano
  • 依托单位:
Novel knockout models to analyze CD38 function
  • 批准号:
    10063339
  • 项目类别:
  • 资助金额:
    $7.8万
  • 财政年份:
    2020
  • 负责人:
    Mireia Guerau-de-Arellano
  • 依托单位:
Epigenetic modulation of T cell tolerance in Multiple Sclerosis autoimmunity
  • 批准号:
    9926829
  • 项目类别:
  • 资助金额:
    $43.89万
  • 财政年份:
    2016
  • 负责人:
    Mireia Guerau-de-Arellano
  • 依托单位:
Novel Epigenetic Modifier Inhibitor Drugs for T cell Modulation in Multiple Sclerosis
  • 批准号:
    9211542
  • 项目类别:
  • 资助金额:
    $22.09万
  • 财政年份:
    2016
  • 负责人:
    Mireia Guerau-de-Arellano
  • 依托单位:
海外基金